Researcher identity and coverage
- Current affiliation
- Not verified in ScienceDex.NIH award organizations may differ from a researcher's employer.
- NIH RePORTER identity
- Profile ID 11325730Search this ID in NIH RePORTER
- ScienceDex PI coverage
- FY2024 through FY2025Career claims are limited to the years shown.Metrics use this researcher's latest loaded PI award year; ScienceDex is current through FY2026.
NIH Funding · FY2025
Linked Award Amount
$2.1M
Full award amounts, FY2025
Award Records
2
Records listing this PI
Award-Linked Rank
#6,142
By linked amount among FY2025 PIs
Earliest Year Loaded
2024
ScienceDex PI coverage
Award-linked funding history
Linked NIH award amounts and rank by fiscal year.
FY2025 award records by amount
NIH award records listing Sarah Marie Hein as a PI. Multi-PI records show the full award amount for context.
- 1R44CA302357-01R44A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphoma$1.1Maward amount
- 5R44CA295245-02R44Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignancies$986.1Kaward amount
Award organization
Organizations that administered FY2025 awards listing Sarah Marie Hein as a PI.
FY2025 award administered by March Biosciences Inc (TX).
Coverage and award-record milestones
Computed from the fiscal years currently available in ScienceDex.
- 2024First NIH AwardMarch Biosciences Inc
- 2024$500K Cumulative Funding
- 2024$1M Cumulative Funding
- 2025$2M Cumulative Funding
- 2025Entered Top 50% NationallyRanked #6142
Shared-award investigators
Other investigators listed on at least one of the same NIH award records as Sarah Marie Hein.